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Saving bones without risking brain - bisphosphonates and risk of stroke: matched case-control 1 
study 2 
Mini Abstract 3 
We investigated the association between bisphosphonate treatment and the risk of stroke using a large 4 
routine clinical dataset. We found no association between bisphosphonate treatment and risk of stroke, 5 
after adjusting for large number of clinical and demographic confounders.  6 
 7 
Abstract 8 
Purpose  9 
There is conflicting evidence on the link between bisphosphonates and stroke with studies variously 10 
showing increased, decreased or unchanged risk.  We investigated the association between 11 
bisphosphonate treatment and the risk of stroke using a large routine clinical dataset. 12 
Methods 13 
We used a matched nested case-control study design analysing routinely collected electronic data 14 
from patients registered at primary care practices in England participating in the Royal College of 15 
General Practitioners Research and Surveillance Centre. Cases were patients aged 18 years or over, 16 
either living or dead, recorded as having had a stroke in the period 1
st
 January 2005 to March 31
st
 17 
2016. Each case was matched to one control according to age, sex, general practice attended and 18 
calendar time. Data were analysed using Stata, version 14.2. Conditional logistic regression was used 19 
to determine odds ratios for stroke according to bisphosphonate treatment and duration in cases 20 
compared with controls. We adjusted for disease risk groups, cardiovascular risk factors, treatments, 21 
smoking status, alcohol consumption, ethnicity , bisphosphonate types, fracture and socioeconomic 22 
status using IMD (Index of Multiple Deprivation). 23 
Results 24 
We included 31,414 cases of stroke with an equal number of matched controls. Overall, 83.2% of 25 
cases and controls were aged 65 years or older and there were similar proportions of females (51.5%) 26 
and males (48.5%). Bisphosphonate treatment was not associated with stroke after adjusting for the 27 
wide range of confounders considered (OR 0.86, 95% CI 0.62 - 1.19). 28 
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Conclusions 1 
We found no association between bisphosphonate treatment and risk of stroke, after adjusting for 2 
other confounders.  3 
 4 
 5 
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Introduction 1 
Screening, prevention and treatment of osteoporosis have increased in the UK, mainland Europe and 2 
the United States due to various factors including the need to address the increasing burden and costs 3 
of fractures, an ageing population at greater risk of fracture, increased awareness of risk factors for 4 
fracture and greater availability of screening tests (bone scans) and screening algorithms.[1] 5 
 6 
According to national guidance in the UK and US, bisphosphonate drugs (alendronate, pamidronate, 7 
risedronate, ibandronate, zoledronic acid) have largely replaced the use of Vitamin D with or without 8 
supplemental calcium for preventing fragility fractures NICE [2] in those deemed to be at-risk,[3, 4] 9 
mainly due to  lack of evidence of effectiveness of the latter.[5, 6] Bisphosphonates prevent bone loss 10 
by slowing down the cells that break down and reabsorb old bone. 11 
 12 
There have also been conflicting systematic reviews about the association with cardiovascular disease 13 
(CVD) of treatments for osteoporosis. Neither calcium[7] nor vitamin D[8], which have been used for 14 
treatment of osteoporosis have been shown to be associated with cardiovascular benefits or adverse 15 
effects. Bisphosphonates, on the other hand, have shown conflicting evidence of CVD risk. 16 
 17 
Previous observational studies have suggested an increased risk, albeit small, of fatal stroke with 18 
bisphosphonates,[9] whereas other studies have not found such an association,[10] or found a 19 
reduction in risk of stroke with these agents.[11] Similar early reviews suggested that some 20 
bisphosphonates could be associated with atrial fibrillation, and although this is a heart rhythm 21 
disorder which in some cases can trigger stroke, these studies showed no association with stroke.[12, 22 
13] More recent reviews have shown no adverse effect on stroke, no reduction in cardiovascular 23 
outcomes overall,[14] but a modest increase in risk of atrial fibrillation.[15] 24 
 25 
We aimed to investigate the association between bisphosphonate treatment and stroke (fatal and non-26 
fatal) using a large routine clinical dataset.  27 
 28 
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Methods1 
Study design  2 
We used a matched nested case-control study design to investigate the effect of bisphosphonates on 3 
risk of stroke. We identified cases (patients with stroke) and controls (patients without stroke) and 4 
compared these for prescriptions of bisphosphonates and other risk factors for stroke prior to the date 5 
of the stroke (or an equivalent date in control patients). Stroke was defined as both ischaemic 6 
and haemorrhagic stroke together with transient ischaemic attack or TIA, which is also known as a 7 
mini-stroke. TIA is the same as a stroke, except that the symptoms last for a short amount of time and 8 
no longer than 24 hours. This is because the blockage that stops the blood getting to the brain is 9 
temporary. 10 
 11 
Key medications including bisphosphonates were defined and grouped using British National 12 
Formulary (BNF) chapter (Table 1). 13 
 14 
  15 
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Table 1 Drugs searched through BNF and defined through EMIS and Read Codes. 1 
Bisphosphonates BNF  6.6.2 Alendronic Acid, Etidronate, Ibandronic Acid, 
Pamidronate Disodium, Risedronate Sodium, 
Tilondronate, Sodium Clodronate, Zoledronic Acid. 
Vasodilator antihypertensive 
drugs 
BNF 2.5.1  Ambrisentan, Bosentan, Hydralazine Hydrochloride, 
Iloprost Macitentan,  Minoxidil, Riociguat, 
Sildenafil,  
Sodium Nitroprusside, Tadalafil. 
Centrally acting 
antihypertensive drugs 
BNF 2.5.2 Clonidine Hydrochloride, Methyldopa, Moxonidine. 
Adrenergic neurone blocking 
drugs 
BNF 2.5.3  Guanethidine Monosulfate. 
Alpha-adrenoceptor blocking 
drugs 
BNF 2.5.4  Doxazosin , Indoramin, Prazosin, Terazosin, 
Phenoxybenzamine Hydrochloride, Phentolamine 
Mesilate 
Angiotensin-converting enzyme 
inhibitors 
BNF 2.5.5.1  Captopril, Enalapril, Maleate Fosinopril Sodium,  
Imidapril Hydrochloride, Lisinopril, Moexipril 
Hydrochloride,  Perindopril, Erbumine, Perindopril, 
Arginine, Quinapril, Ramipril, Ramipril with 
Felodipine, Trandolapril. 
Angiotensin-II receptor 
antagonists 
BNF 2.5.5.2  Azilsartan, Candesartan, Eprosartan, Irbesartan, 
Losartan, Olmesartan, Telmisartan, Valsartan. 
Renin inhibitors BNF 2.5.5.3 Aliskiren. 
Calcium-channel blockers BNF 2.6.2  Amlodipine, Diltiazem Hydrochloride, Felodipine, 
Isradipine, Lacidipine, Lercanidipine Hydrochloride,  
Nicardipine Hydrochloride, Nifedipine, Nimodipine,  
Verapamil Hydrochloride. 
Statin   (Read & EMIS 
Codes) 
Atorvastatin, Fluvastatin, Pravastatin Sodium, 
Rosuvastatin, Simvastatin, Simvastatin with 
Ezetimibe, Simvastatin with Fenofibrate. 
Oral anticoagulant  (Read & EMIS 
Codes) 
Warfarin Sodium, Acenocoumarol, Phenindione, 
Dabigatran, Etexilate, Rivaroxaban, Apixaban. 
 2 
We searched routinely collected electronic records from patients in England registered at primary care 3 
practices who are members of the Royal College of General Practitioners (RCGP) Research and 4 
Surveillance Centre (RSC).[16] This is a large computerised anonymised database representative of 5 
and comprising 2.9% of the population of England [17] including demographic information, data on 6 
health behaviours, referrals and treatment outcomes, with good clinical information including stroke 7 
and stroke deaths.[18] The study observational period was 1 January 2005 to 31 March 2016.  8 
 9 
  10 
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Selection of cases and controls 1 
The study cohort included patients drawn from all RCGP RSC practices over 10 years. Cases were 2 
patients aged 18 or over, either living or dead, recorded with standard computer codes for stroke.  3 
Each case of stroke was matched to one control according to age, sex, general practice attended and 4 
calendar time. Controls were patients registered at the same practice during the study period identified 5 
at the same index date as the corresponding case to account for possible seasonal effects and effects 6 
due to duration of observation for events. Controls were selected at random (and before their exposure 7 
status was known to reduce selection bias) from the pool of eligible matched controls for each case 8 
using incidence density sampling according to person-time at risk.[19] Controls had to be alive and 9 
not transferred out of the practice or dead prior to the index date of their matched case. All cases and 10 
controls that had less than 5 years of clinical records before the index date on the dataset were 11 
excluded to ensure completeness of recording of exposures and confounding variables. Those with a 12 
previous diagnosis of stroke were also excluded. For identified cases, the index date was the date of 13 
the first Stroke/TIA suffered by the patient. For the control, the index date was the date the patient 14 
they are matched to suffered their first stroke within the study period. The case was only stopped if it 15 
had deceased during the observational period. 16 
 17 
Outcomes, exposures, confounder and effect modifiers 18 
Outcome measures were unadjusted and adjusted odds ratios and 95% confidence intervals for stroke 19 
associated with bisphosphonate treatment prior to the index date. Quintiles of the Index of Multiple 20 
Deprivation (IMD) were used as it ranks every small area in England from 1 to 32,844 (most deprived 21 
area to least deprived area) and Charlson Comorbidity Index (CCI) was used as a proxy for level of 22 
risk and frailty. [1] We adjusted for known confounding variables, in particular disease risk groups 23 
associated with stroke, cardiovascular risk factors, treatments, and other factors (ethnicity, Charlson 24 
comorbidity index,  Index of Multiple Deprivation (IMD score) recorded with a computer (Read or 25 
EMIS) code. Fractures and bisphosphonate types were also included as confounding variables.  26 
 27 
Data analysis 28 
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Data were analysed using Stata, version 14.2 initially with some work done during the revision period 1 
using RStudio version 1.1.463. Descriptive statistics were given in terms of frequencies for 2 
categorical variables and means with standard deviations for continuous variables. We used 3 
conditional logistic regressions for matched case control studies, calculating unadjusted and adjusted 4 
odds ratios with 95% confidence intervals for stroke according to bisphosphonate treatment and 5 
duration in cases compared with controls. Adjusted analysis accounted for disease risk groups, 6 
cardiovascular risk factors, treatments, smoking status, alcohol consumption, fracture types, 7 
bisphosphonate types, ethnicity and socioeconomic status using the Index of Multiple Deprivation. 8 
All the confounding variables are listed in Tables (2-4). Fracture types, hip, osteonecrosis of the jaw 9 
(ONJ), vertebral and other fractures were grouped together. Bisphosphonate types were derived from 10 
Table 1. 11 
 12 
Ethical approval 13 
We obtained ethical approval from Lincolnshire Community Health Services NHS Trust and the 14 
University of Lincoln, School of Health and Social Sciences Ethics Committee, the research protocol 15 
was approved by RCGP RSC. 16 
 17 
Results 18 
Unadjusted analysis 19 
We included 31,414 cases of stroke with an equal number of matched controls (Table 2). Overall 20 
83.2% in both cases and controls were aged 65 years or older and there were similar proportions of 21 
females and males (51.5% females and 48.5% males).  22 
 23 
All the disease risk groups included in the analysis had a negative impact on the risk of stroke, with 24 
atrial fibrillation, peripheral arterial disease and hemiplegia being the groups with the highest impact 25 
on stroke (unadjusted OR of 2.13, 2.04 and 5.45 respectively; see Table 3). For cardiovascular risk 26 
factors (Table 2), being an ex-smoker, never smoker or non-drinker was associated with a reduced 27 
risk of stroke (unadjusted OR of 0.86, 0.82 and 0.82 respectively). The remaining cardiovascular risk 28 
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factors also had a negative impact on the risk of stroke, except high-density lipoprotein (HDL) 1 
cholesterol.  2 
 3 
In relation to treatments (Table 4), we found that all were associated with a higher risk of stroke, with 4 
aspirin, statins and oral anticoagulants having the strongest association (unadjusted odds ratios of 5 
1.79, 1.45 and 1.47, respectively). The unadjusted analysis also showed that a greater number of 6 
comorbidities were associated with a higher risk of stroke. Finally, the Index of Multiple Deprivation 7 
(IMD score) showed that people living in the most deprived areas had a higher risk of stroke than 8 
those living in the least deprived ones (without considering any other confounding). 9 
The number of patients who had received bisphosphonates was greater for the cases than for controls: 10 
9.3% of cases were prescribed bisphosphonates, while 7.6% of patients in the control group had 11 
received a prescription. The unadjusted odds ratio (OR) for the bisphosphonate treatment was 1.27, 12 
indicating that patients taking bisphosphonates were 27% more likely to suffer stroke than patients 13 
with no treatment, without considering any confounding variables. 14 
 15 
Alendronate , Ibandronate and Risedronate showed reduced risk (unadjusted OR 0.78, 0.66, and 0.84 16 
respectively) of association with stroke, and fracture types were not statistically significant for the 17 
unadjusted analysis. Most patients with lower CCI index took Alendronate followed by Risedronate 18 
and Ibandronate, Figure (1).  Alendronate remained the preferred bisphosphonate of choice even as 19 
CCI index increased, showing highest prescription number for the first CCI index. 20 
 21 
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 1 
Figure 1. Showing number of bisphosphonate prescriptions uptake against Charlson Comobidity 2 
Index. 3 
Adjusted analysis 4 
Table 5 shows the results of the adjusted analysis, where we included all the variables in the same 5 
regression to adjust for other confounders. The adjusted OR for the bisphosphonate treatment was 6 
0.86 (95% CI 0.62 - 1.19) indicating the absence of a relationship between the drug and stroke, once 7 
all other confounding variables had been taken into account. 8 
 9 
Among the disease risk groups, hemiplegia, atrial fibrillation and peripheral arterial disease were the 10 
variables with the highest effect on the risk of having stroke (OR 4.59, 1.98 and 1.48, respectively). 11 
Some of the disease risk groups included in the analysis, such as hyperlipidaemia, diabetes, chronic 12 
renal disease, Chronic Obstructive Pulmonary Disease (COPD), mild liver disease, peptic ulcer and 13 
rheumatological disease, showed a non-significant effect on the risk of stroke, when they were 14 
considered in the adjusted analysis. 15 
 16 
Alcoholism (OR 1.43, 95% CI 1.30-1.57) and most deprived  IMD (OR 1.27, 95% CI 1.18-1.37) were 17 
the risk factors showing the highest association with risk of stroke. Being a safe drinker was 18 
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associated with a lower risk of stroke (OR 0.84, 95% CI 0.80-0.88) compared to someone who had 1 
never drank alcohol, as were those on warfarin (OR 0.40, 95% CI 0.37-0.59). 2 
 3 
The treatment associated with the highest risk of stroke was aspirin (OR 1.44, 95% CI 1.38-1.50), 4 
whereas antihypertensive treatment was associated with a reduced risk of stroke (OR 0.92). Finally, 5 
looking at IMD score, we found that patients living in the most deprived areas were more likely to 6 
suffer stroke compared to those living in the least deprived areas, as previously shown in the 7 
unadjusted analysis. The CCI showed a lower gradient than for the unadjusted analysis but still 8 
showed slight increase in odds ratio as number of comorbidities increased. 9 
 10 
 11 
 12 
 13 
Table 2 Characteristics of cases of stroke and matched controls 14 
Variables 
Cases N=31,414,  
N (%) 
Controls 
N=31,414,  
N (%) 
Unadjusted OR 
(95% CI) 
P-Value 
Matching variables     
Age 
    
18-24 years 37 (0.1) 37 (0.1) 
  
25-34 years 178 (0.6) 178 (0.6) 
  
35-44 years 404 (1.3) 404 (1.3) 
  
45-54 years 1561 (5) 1561 (5) NA 
 
55-64 years 3109 (9.9) 3109 (9.9) 
  
≥65 years 26125 (83.2) 26125 (83.2) 
  
  
Sex 
 
Female 16331 (52) 16331 (52) NA 
 
Male 15083 (48) 15083 (48) 
  
  
     
Ethnicity 
    
White 21462 (68.3) 19004 (60.5) ref 
 
Asian 633 (2) 577 (1.8) 0.92 (0.81 - 1.05) 0.22 
Black 493 (1.6) 384 (1.2) 1.09 (0.94 - 1.27) 0.25 
Mixed 104 (0.3) 106 (0.3) 1.16 (0.87 - 1.56) 0.32 
Other 86 (0.3) 107 (0.3) 0.72 (0.54 - 0.97) 0.03 
Missing 8636 (27.5) 11236 (35.8) 
  
     
Fracture
*
     
Hip 355 (1.13%) 246 (0.78%) ref  
ONJ 10 (0.03%) 9 (0.03%) 1.30 (0.50 - 3.31) 0.58 
Other Fracture 2595 (8.26%) 1871 (5.96%) 1.04 (0.88 - 1.24) 0.655 
None 28322 (90.2%) 29193 (92.9%) 1.49 (1.26 - 1.75) p<0.001 
     
11 
 
 1 
╫ Some patients may have taken more than one type of Bisphosphonate over their prescription period. Only 1 person was 2 
prescribed  Pamidronate so it is excluded in the table  above. 3 
*Fracture and Bisphosphonate types added using RStudio.[20]  4 
  5 
IMD quintile 
    
1-Most deprived 4575 (14.6) 4114 (13.1) ref 
 
2 4704 (15) 4449 (14.2) 1.35 (1.25 - 1.45) p<0.001 
3 6060 (19.3) 6059 (19.3) 1.19 (1.12 - 1.27) p<0.001 
4 7418 (23.6) 7381 (23.5) 1.16 (1.10 - 1.22) p<0.001 
5-Least deprived 8596 (27.4) 9116 (29.0) 1.07 (1.02 - 1.13) p<0.001 
Missing 61 (0.2) 295 (0.9) 
  
     
     
Bisphosphonate Types
╫*
     
Alendronate 1975(6.29) 2488(7.92) 0.78 (0.73 - 0.83) <0.001 
none 29439(93.7) 28926(92.1) ref  
Clodronate 23(0.07) 18(0.06) 1.28 (0.69 - 2.40) 0.441 
none 31391(99.9) 31396(99.9) ref  
Etidronate 101(0.32) 88(0.28) 1.15 (0.86 - 1.53) 0.345 
none 31313(99.7) 31326(99.7) ref  
Ibandronate 88(0.28) 133(0.42) 0.66 (0.50 - 0.86) 0.002 
none 31326(99.7) 31281(99.6) ref  
Risedronate 416(1.32) 494(1.57) 0.84 (0.74 - 0.96) 0.009 
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Table 3 Disease risk groups and cardiovascular risk factors 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
Variables 
Cases N=31,414, 
N (%) 
Controls 
N=31,414, N (%) 
 Unadjusted OR 
(95% CI) 
P-Value 
Disease risk groups 
    
CKD 6037 (19.2) 4670 (14.9) 1.42 (1.36 - 1.48) p<0.001 
COPD 2018 (6.4) 1615 (5.1) 1.28 (1.19 - 1.37) p<0.001 
Diabetes 4922 (15.7) 3644 (11.6) 1.43 (1.36 - 1.50) p<0.001 
Diabetes with complications 1635 (5.2) 973 (3.1) 1.74 (1.60 - 1.89) p<0.001 
Hyperlipidaemia 2934 (9.3) 2342 (7.5) 1.31 (1.24 - 1.39) p<0.001 
Acute myocardial infarction 1007 (3.2) 669 (2.1) 1.53 (1.39 - 1.69) p<0.001 
Angina 1555 (5.0) 1172 (3.7) 1.36 (1.26 - 1.48) p<0.001 
Atrial fibrillation 3290 (10.5) 1687 (5.4) 2.13 (2.00 - 2.27) p<0.001 
Congestive cardiac failure 1173 (3.7) 884 (2.8) 1.35 (1.23 - 1.48) p<0.001 
Hypertension 11134 (35.4) 8589 (27.3) 1.53 (1.47 - 1.58) p<0.001 
Peripheral arterial disease 771 (2.5) 389 (1.2) 2.04 (1.80 - 2.31) p<0.001 
Hemiplegia 258 (0.8) 36 (0.1) 5.45 (3.99 - 7.43) p<0.001 
Mild liver disease 257 (0.8) 176 (0.6) 1.47 (1.22 - 1.79) p<0.001 
Moderate liver disease 71 (0.2) 51 (0.2) 1.25 (0.88 - 1.77) 0.22 
Peptic ulcer 474 (1.5) 294 (0.9) 1.59 (1.38 - 1.84) p<0.001 
Rheumatological disease 945 (3.0) 707 (2.3) 1.36 (1.23 - 1.5) p<0.001 
Cancer 3034 (9.7) 2870 (9.1) 1.07 (1.01 - 1.13) 0.02 
Dementia 2041(6.5) 1440 (4.6) 1.51 (1.40 - 1.62) p<0.001 
  
Cardiovascular risk factors 
 
Family history     
Family history of stroke 1384 (4.4) 1054 (3.4) 1.34 (1.23 - 1.46) p<0.001 
Family history of ischemic 
heart disease 
2109 (6.7) 1906 (6.1) 1.18 (1.10 - 1.26) p<0.001 
     
Smoking     
Active 699 (2.2) 431 (1.4) ref  
Ex-Smoker 1898 (6) 1524 (4.9) 0.86 (0.75 - 0.99) 0.04 
Never 1387 (4.4) 1224 (3.9) 0.82 (0.71 - 0.94) 0.01 
Missing 27430 (87.3) 28235 (89.9)   
     
Alcohol consumption 
category 
    
Non-drinker 7333 (23.3) 6549 (20.9) ref  
Safe 9580 (30.5) 10402 (33.1) 0.82 (0.79 - 0.87) p<0.001 
Hazardous 8935 (28.4) 8205 (26.1) 1.01 (0.95 - 1.06) 0.82 
Alcoholism 1589 (5.1) 958 (3.1) 1.51 (1.37 - 1.66) p<0.001 
Missing 3977 (12.7) 5300 (16.9)   
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Table 4 Clinical measurements, treatments (including bisphosphonates) and Charlson Index 1 
 2 
 3 
 4 
 5 
 6 
Variables 
Cases 
N=31,414, 
N (%) 
Controls 
N=31,414, N 
(%) 
Unadjusted OR 
(95% CI) 
P-
Value 
Clinical measurements 
 
Body Mass Index recorded 17973 (57.2) 16140 (51.4) 
  
Body Mass Index kg/m² (mean [SD]) 27.3[5.5] 27.0[5.4] 1.01 (1.0 - 1.02) p<0.001 
Systolic blood pressure recorded 24171 (76.9) 22258 (70.9) 
  
Systolic blood pressure mmHg (mean 
[SD]) 
137.8 [19.1] 136.1 [18.1] 1.01 (1.01 - 1.01) p<0.001 
Diastolic blood pressure recorded 24171 (76.9) 22258 (70.9) 
  
Diastolic blood pressure mmHg (mean 
[SD]) 
77.6 [11.1] 76.8 [10.6] 1.02 (1.01 - 1.02) 0.04 
LDL recorded 14061 (44.8) 11296 (36) 
  
LDL mmols/l  (mean [SD]) 2.9  2.8  1.04 (1.00 - 1.07) p<0.001 
HDL recorded 16682 (53.1) 13555 (43.1) 
  
HDL mmols/l  (mean [SD]) 1.5 [0.5] 1.5  0.90 (0.84 - 0.96) p<0.001 
Total cholesterol recorded 18836 (60.0) 15284 (48.7) 
  
Total cholesterol mmols/l  (mean [SD]) 5.0 [1.2] 5.0 [1.2] 1.04 (1.01 - 1.06) p<0.001 
Weekly alcohol units recorded 3370 (10.7) 3881 (12.4) 
  
Weekly alcohol units (mean [SD]) 6.7 [13.6] 6.6 [12.8] 1.00 (1.00 - 1.01) 0.74 
     
Treatments 
 
Aspirin uptake 11112 (35.4) 7660 (24.4) 1.79 (1.72 - 1.85) p<0.001 
Antihypertensive treatment 11963 (38.1) 9544 (30.4) 1.43 (1.38 - 1.48) p<0.001 
Statin uptake 10998 (35) 8768 (27.9) 1.45 (1.40 - 1.50) p<0.001 
Oral anticoagulant 2109 (6.7) 1655 (5.3) 1.3 (1.22 - 1.39) p<0.001 
Calcium uptake 10639 (33.9) 8447 (26.9) 1.47 (1.41 - 1.52) p<0.001 
Vitamin D uptake 4782 (15.2) 3830 (12.2) 1.35 (1.28 - 1.42) p<0.001 
Warfarin 1987 (6.3) 1615 (5.1) 1.25 (1.17 - 1.34) p<0.001 
     
Bisphosphonates     
Bisphosphonates uptake (last 3 years) 2909 (9.3) 2384 (7.6) 1.27 (1.19-1.34) p<0.001 
Number of bisphosphonate prescriptions 
(mean  [SD]) 
24.0 [27.9] 22.2 [27.9]   
     
Charlson Index 
 
0 12116 (38.6) 15850 (50.5) ref 
 
1 7170 (22.8) 6072 (19.3) 1.65 (1.58 - 1.73) p<0.001 
2 4612 (14.7) 3668 (11.7) 1.81 (1.71 - 1.91) p<0.001 
3 3454 (11) 2700 (8.6) 1.89 (1.78 - 2.01) p<0.001 
4 1917 (6.1) 1413 (4.5) 2.09 (1.94 - 2.26) p<0.001 
≥5 2145 (6.8) 1711 (5.5) 2.05 (1.92 - 2.19) p<0.001 
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Table 5 Conditional logistic regression for matched cases and controls model adjusted for 1 
confounders 2 
Stroke/TIA   
Odds 
Ratio 
[95% 
Conf. 
Interval] P-value 
 
     
 
All Bisphosphonates  0.86 0.62 1.19 0.35 
Bisphosphonates Types 
    
 
Alendronate                                                                                                                             1.13 0.81 1.57 0.46 
 
Clodronate 0.98 0.46 2.08 0.96 
 
Etidronate 0.89 0.57 1.40 0.61 
 
Ibandronate 1.31 0.83 2.06 0.24 
 
Risedronate 1.12 0.79 1.58 0.54 
 
ZoledronicAcid 0.79 0.21 2.95 0.73 
Drugs 
 
    
 
Calcium 0.94 0.9 0.99 0.03 
 
VitaminD 0.94 0.87 1.01 0.07 
 
Aspirin 1.44 1.38 1.50 p<0.001 
 
Antihypertensive 0.92 0.88 0.97 p<0.001 
 
Statins 0.99 0.95 1.04 0.83 
 
Warfarin 0.40 0.27 0.59 p<0.001 
 
Oral AntiCoagulant Therapy 1.87 1.27 2.75 p<0.001 
Diseases 
     
 
Chronic kidney disease 0.95 0.88 1.01 0.1 
 
Chronic Obstructive Pulmonary 
Disease 
0.97 0.91 1.06 0.71 
 
Diabetes 0.97 0.91 1.03 0.3 
 
Acute myocardial infarction 1.13 1.01 1.25 0.03 
 
Angina 0.97 0.89 1.05 0.44 
 
Atrial fibrillation 1.98 1.83 2.13 p<0.001 
 
Congestive cardiac failure 0.91 0.82 1.01 0.07 
 
Hypertension 1.11 1.05 1.17 p<0.001 
 
Peripheral arterial disease 1.48 1.30 1.69 p<0.001 
 
Hemiplegia 4.59 3.33 6.34 p<0.001 
 
Immunosuppression 0.98 0.83 1.16 0.79 
 
Mild liver disease 0.95 0.77 1.17 0.65 
 
Moderate liver disease 0.73 0.50 1.07 0.11 
 
Peptic ulcer 1.25 1.07 1.46 p<0.001 
 
Rheumatological disease 1.11 0.99 1.24 0.07 
 
Hyperlipidaemia 1.09 1.02 1.16 0.01 
Life Style 
     
 
Active smoker 1.15 0.99 1.33 0.07 
 
Ex-smoker 1.00 0.90 1.11 0.98 
 
Safe alcohol consumption  0.84 0.80 0.88 p<0.001 
 
Hazardous alcohol consumption 0.96 0.92 1.02 0.18 
 
Alcoholism 1.43 1.30 1.57 p<0.001 
Fracture 
     
 
Hip 1.39 1.17 1.66 p<0.001 
 
ONJ 1.09 0.43 2.75 p0.85 
 
Other Fractures 1.35 1.26 1.45 p<0.001 
 
Vertebral 1.33 1.01 1.76 0.05 
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Deprivation Quintiles 
    
 
DeprivationQuintile1 1.27 1.18 1.37 p<0.001 
 
DeprivationQuintile2 1.15 1.07 1.22 p<0.001 
 
DeprivationQuintile3 1.13 1.07 1.2 p<0.001 
 
DeprivationQuintile4 1.06 1.01 1.12 0.01 
Co-morbidity 
 
    
 
CharlsonI1 1.37 1.30 1.45 p<0.001 
 
CharlsonI2 1.45 1.35 1.55 p<0.001 
 
CharlsonI3 1.41 1.29 1.54 p<0.001 
 
CharlsonI4 1.45 1.29 1.62 p<0.001 
  CharlsonI5 1.38 1.21 1.56 p<0.001 
Analysis performed using R package Survival. [21] 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
  10 
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Discussion 1 
Main findings 2 
We found no association between bisphosphonate treatment and risk of stroke, after adjusting for age, 3 
sex, ethnicity, index of multiple deprivation, Charlson index, Fracture status, clinical and treatment 4 
variables.  5 
 6 
Strengths and limitations 7 
The limitations of the case-control approach include confounding and residual unmeasured 8 
confounding. The large validated database we used enabled us to adjust for important confounders 9 
including clinical risk groups, cardiovascular risk factors and differences in treatment between cases 10 
and controls. We also adjusted for additional comorbidities using the Charlson index. Although great 11 
care was taken to ensure all stroke/TIAs were correctly coded, around 20% of all stroke patients’ are 12 
those who have temporary symptoms of TIA episodes.[22] These are difficult to diagnose as they 13 
depend on patient history. Because the duration of the episode is short, patients’ symptoms are likely 14 
to have resolved by the time of assessment, and the absence of an established biomarker makes the 15 
diagnosis difficult. Information about physical activity and diet were not available and these factors 16 
may be a source of residual confounding. 17 
 18 
Comparison with previous studies 19 
The previous contradictory evidence linking bisphosphonates and stroke provided the rationale for 20 
this study. Although bisphosphonates have been associated with atrial fibrillation, presumed to be an 21 
idiosyncratic adverse effect which can sometimes lead to an embolic stroke due to thrombus 22 
generated in the abnormally contracting atrium blocking a narrowed carotid artery, there was no 23 
association with stroke in these studies.[12, 13]    24 
 25 
Other studies have suggested that bisphosphonates may prevent cardiovascular disease including 26 
stroke and myocardial infection mediated through a reduction in vascular calcification or reduced 27 
atherosclerosis through a number of mechanisms.[23] Vestergaard and colleagues, in a large cohort 28 
17 
 
study in Denmark found a reduction in overall risk of cardiovascular events but an increase in fatal 1 
strokes but the variability in effect for different drugs and the differences in risk observed were 2 
small.[9]  3 
 4 
One study showed no association between prior bisphosphonate therapy and 30-day mortality from 5 
stroke.[24] The most recently published meta-analysis, from Kim and colleagues, concluded that 6 
‘bisphosphonates do not have beneficial or harmful effects on atherosclerotic cardiovascular events, 7 
but zoledronic acid may modestly increase the risk of atrial fibrillation’.[15] 8 
 9 
Bisphosphonate Compliance 10 
There is a question about those patients who are possibly at a higher risk may have been less likely to 11 
take the bisphosphonates, figure (1). Generally, there is a problem with compliance as Park and 12 
colleagues have shown that compliance and persistence with oral bisphosphates in patients with 13 
rheumatoid arthritis were suboptimal in real practice, thereby limiting the efficacy of osteoporosis 14 
treatment. [25]This may be true for our study as well. 15 
 16 
Implications for policy, practice and research 17 
This study suggests that bisphosphonate as a group of drugs are not associated with increased risk of 18 
stroke. This and evidence of effectiveness for prevention of osteoporosis supports their use first-line 19 
for prevention of osteoporosis in those deemed to be at high risk.[2] Clinicians will continue to use 20 
these drugs but greater consideration is being given to the time to stop [26] because of a lack of 21 
benefit beyond this time. There is limited evidence that bisphosphonates can cause painful, hard-to-22 
treat osteonecrosis damage to the jaw bone, as well as very rare fractures of the mid-femur, further 23 
research is needed in these areas to shed more light. Our study finds no evidence for excess ONJ 24 
fracture due to bisphosphonates however there were noticeably more hip and other fractures present in 25 
the cases. Finally, we recommend further research to incorporate other confounders, to conduct 26 
studies which overcome unknown or unmeasured confounders for example using self-controlled case 27 
series designs.  28 
18 
 
 1 
Conclusion  2 
We found no association between bisphosphonate treatment and risk of stroke, after adjusting for 3 
other confounders. Bisphosphonates are considered first-line for prevention of osteoporosis and 4 
fragility fractures and this study supports their safety in people at risk of stroke. 5 
 6 
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